Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: INPPL1

Gene summary for INPPL1

Gene summary.

Gene information	Species	Human
	Gene symbol	INPPL1
	Gene ID	3636
	Gene name	inositol polyphosphate phosphatase like 1
	Gene Alias	OPSMD
	Cytomap	11q13.4
	Gene Type	protein-coding
	GO ID	GO:0001501
	UniProtAcc	O15357

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
3636	INPPL1	P62T-E	Human	Esophagus	ESCC	7.53e-10	1.23e-01	0.1302
3636	INPPL1	P74T-E	Human	Esophagus	ESCC	5.32e-11	1.76e-01	0.1479
3636	INPPL1	P75T-E	Human	Esophagus	ESCC	4.83e-15	2.38e-01	0.1125
3636	INPPL1	P76T-E	Human	Esophagus	ESCC	1.04e-27	3.31e-01	0.1207
3636	INPPL1	P79T-E	Human	Esophagus	ESCC	7.50e-16	9.95e-02	0.1154
3636	INPPL1	P80T-E	Human	Esophagus	ESCC	8.28e-03	7.00e-02	0.155
3636	INPPL1	P82T-E	Human	Esophagus	ESCC	8.86e-04	1.91e-01	0.1072
3636	INPPL1	P83T-E	Human	Esophagus	ESCC	3.73e-20	5.02e-01	0.1738
3636	INPPL1	P107T-E	Human	Esophagus	ESCC	2.16e-05	1.21e-01	0.171
3636	INPPL1	P128T-E	Human	Esophagus	ESCC	5.34e-18	5.04e-01	0.1241
3636	INPPL1	P130T-E	Human	Esophagus	ESCC	2.57e-17	2.56e-01	0.1676
3636	INPPL1	HCC1_Meng	Human	Liver	HCC	2.53e-24	5.38e-02	0.0246
3636	INPPL1	HCC2_Meng	Human	Liver	HCC	1.71e-10	7.76e-02	0.0107
3636	INPPL1	HCC2	Human	Liver	HCC	8.26e-03	2.04e+00	0.5341
3636	INPPL1	S014	Human	Liver	HCC	1.55e-08	3.89e-01	0.2254
3636	INPPL1	S015	Human	Liver	HCC	7.27e-08	5.19e-01	0.2375
3636	INPPL1	S016	Human	Liver	HCC	1.04e-09	4.89e-01	0.2243
3636	INPPL1	S027	Human	Liver	HCC	8.56e-05	5.73e-01	0.2446
3636	INPPL1	S028	Human	Liver	HCC	3.36e-17	6.82e-01	0.2503
3636	INPPL1	S029	Human	Liver	HCC	1.20e-19	6.85e-01	0.2581

Page: 1 2 3 4 5

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0007015	Colorectum	AD	actin filament organization	167/3918	442/18723	1.65e-16	7.94e-14	167
GO:0032868	Colorectum	AD	response to insulin	91/3918	264/18723	2.02e-07	8.48e-06	91
GO:0043434	Colorectum	AD	response to peptide hormone	126/3918	414/18723	2.70e-06	7.86e-05	126
GO:0016311	Colorectum	AD	dephosphorylation	123/3918	417/18723	1.84e-05	3.82e-04	123
GO:0019318	Colorectum	AD	hexose metabolic process	77/3918	237/18723	1.96e-05	4.01e-04	77
GO:0005996	Colorectum	AD	monosaccharide metabolic process	80/3918	257/18723	7.31e-05	1.17e-03	80
GO:0030258	Colorectum	AD	lipid modification	67/3918	212/18723	1.66e-04	2.27e-03	67
GO:0006006	Colorectum	AD	glucose metabolic process	62/3918	196/18723	2.76e-04	3.39e-03	62
GO:0009791	Colorectum	AD	post-embryonic development	29/3918	80/18723	1.13e-03	1.03e-02	29
GO:0006650	Colorectum	AD	glycerophospholipid metabolic process	83/3918	306/18723	5.40e-03	3.55e-02	83
GO:0006644	Colorectum	AD	phospholipid metabolic process	101/3918	383/18723	5.80e-03	3.67e-02	101
GO:0001503	Colorectum	AD	ossification	106/3918	408/18723	7.68e-03	4.64e-02	106
GO:0045017	Colorectum	AD	glycerolipid biosynthetic process	69/3918	252/18723	8.33e-03	4.88e-02	69
GO:00070151	Colorectum	SER	actin filament organization	134/2897	442/18723	1.39e-15	5.70e-13	134
GO:00328681	Colorectum	SER	response to insulin	65/2897	264/18723	6.70e-05	1.53e-03	65
GO:00434341	Colorectum	SER	response to peptide hormone	93/2897	414/18723	9.61e-05	2.04e-03	93
GO:00193181	Colorectum	SER	hexose metabolic process	56/2897	237/18723	6.19e-04	8.42e-03	56
GO:00059961	Colorectum	SER	monosaccharide metabolic process	59/2897	257/18723	9.65e-04	1.15e-02	59
GO:00060061	Colorectum	SER	glucose metabolic process	46/2897	196/18723	2.08e-03	2.05e-02	46
GO:0046486	Colorectum	SER	glycerolipid metabolic process	82/2897	392/18723	2.26e-03	2.17e-02	82

Page: 1 2 3 4 5 6 7

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa046662	Colorectum	SER	Fc gamma R-mediated phagocytosis	39/1580	97/8465	5.84e-07	9.70e-06	7.04e-06	39
hsa046663	Colorectum	SER	Fc gamma R-mediated phagocytosis	39/1580	97/8465	5.84e-07	9.70e-06	7.04e-06	39
hsa046664	Colorectum	MSS	Fc gamma R-mediated phagocytosis	45/1875	97/8465	9.30e-08	1.56e-06	9.55e-07	45
hsa04910	Colorectum	MSS	Insulin signaling pathway	43/1875	137/8465	7.37e-03	2.84e-02	1.74e-02	43
hsa046665	Colorectum	MSS	Fc gamma R-mediated phagocytosis	45/1875	97/8465	9.30e-08	1.56e-06	9.55e-07	45
hsa049101	Colorectum	MSS	Insulin signaling pathway	43/1875	137/8465	7.37e-03	2.84e-02	1.74e-02	43
hsa046668	Colorectum	CRC	Fc gamma R-mediated phagocytosis	27/1091	97/8465	6.24e-05	1.12e-03	7.57e-04	27
hsa04070	Colorectum	CRC	Phosphatidylinositol signaling system	25/1091	97/8465	4.27e-04	4.60e-03	3.12e-03	25
hsa049104	Colorectum	CRC	Insulin signaling pathway	31/1091	137/8465	1.07e-03	8.91e-03	6.03e-03	31
hsa00562	Colorectum	CRC	Inositol phosphate metabolism	18/1091	73/8465	4.38e-03	2.52e-02	1.71e-02	18
hsa046669	Colorectum	CRC	Fc gamma R-mediated phagocytosis	27/1091	97/8465	6.24e-05	1.12e-03	7.57e-04	27
hsa040701	Colorectum	CRC	Phosphatidylinositol signaling system	25/1091	97/8465	4.27e-04	4.60e-03	3.12e-03	25
hsa049105	Colorectum	CRC	Insulin signaling pathway	31/1091	137/8465	1.07e-03	8.91e-03	6.03e-03	31
hsa005621	Colorectum	CRC	Inositol phosphate metabolism	18/1091	73/8465	4.38e-03	2.52e-02	1.71e-02	18
hsa049109	Esophagus	ESCC	Insulin signaling pathway	89/4205	137/8465	1.97e-04	7.32e-04	3.75e-04	89
hsa0466620	Esophagus	ESCC	Fc gamma R-mediated phagocytosis	63/4205	97/8465	1.63e-03	4.89e-03	2.50e-03	63
hsa0491014	Esophagus	ESCC	Insulin signaling pathway	89/4205	137/8465	1.97e-04	7.32e-04	3.75e-04	89
hsa04666110	Esophagus	ESCC	Fc gamma R-mediated phagocytosis	63/4205	97/8465	1.63e-03	4.89e-03	2.50e-03	63
hsa0491041	Liver	HCC	Insulin signaling pathway	95/4020	137/8465	1.53e-07	1.97e-06	1.10e-06	95
hsa0466610	Liver	HCC	Fc gamma R-mediated phagocytosis	58/4020	97/8465	9.65e-03	2.52e-02	1.40e-02	58

Page: 1 2

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

INPPL1

SNV

Missense_Mutation

c.409N>A

p.Glu137Lys

p.E137K

O15357

protein_coding

tolerated(0.13)

possibly_damaging(0.76)

TCGA-A2-A0EQ-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

INPPL1

SNV

Missense_Mutation

c.1214N>A

p.Cys405Tyr

p.C405Y

O15357

protein_coding

deleterious(0)

probably_damaging(0.996)

TCGA-A8-A09Z-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

INPPL1

SNV

Missense_Mutation

c.1408N>C

p.Gly470Arg

p.G470R

O15357

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-AC-A23C-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

chemo

INPPL1

SNV

Missense_Mutation

c.3556C>A

p.Pro1186Thr

p.P1186T

O15357

protein_coding

tolerated(0.58)

benign(0.018)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

INPPL1

SNV

Missense_Mutation

novel

c.2515N>T

p.Val839Phe

p.V839F

O15357

protein_coding

deleterious(0)

benign(0.386)

TCGA-AN-A0FW-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Unknown

INPPL1

SNV

Missense_Mutation

c.2653N>T

p.Leu885Phe

p.L885F

O15357

protein_coding

deleterious(0.02)

possibly_damaging(0.737)

TCGA-D8-A1XQ-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

INPPL1

SNV

Missense_Mutation

rs376117918

c.1636G>A

p.Val546Ile

p.V546I

O15357

protein_coding

tolerated(0.13)

benign(0.179)

TCGA-E2-A1LL-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

docetaxel

INPPL1

SNV

Missense_Mutation

novel

c.629N>A

p.Thr210Asn

p.T210N

O15357

protein_coding

deleterious(0.02)

possibly_damaging(0.806)

TCGA-OL-A5D7-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

cytoxan

INPPL1

SNV

Missense_Mutation

novel

c.1681N>T

p.His561Tyr

p.H561Y

O15357

protein_coding

deleterious(0)

probably_damaging(0.99)

TCGA-Z7-A8R6-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

taxol

INPPL1

insertion

Frame_Shift_Ins

novel

c.780_781insGTTTCACCATGTTGGCCAGGGTGGT

p.Leu261ValfsTer51

p.L261Vfs*51

O15357

protein_coding

TCGA-A2-A0CP-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
3636	INPPL1	KINASE, ENZYME, DRUGGABLE GENOME		ANTISENSE OLIGONUCLEOTIDES		10958682
3636	INPPL1	KINASE, ENZYME, DRUGGABLE GENOME	inhibitor	252827535

Page: 1